A new analytical method for simultaneously measuring three antiviral compounds—including remdesivir—in patient samples has been validated by researchers this week, offering a faster, more precise way to monitor drug levels in hospitalized COVID-19 patients. The technique, published in this week’s Journal of Chromatography B, uses high-performance liquid chromatography with fluorescence detection (HPLC-FLD) to quantify remdesivir, its active metabolite GS-441524, and a third antiviral agent in a single test. Experts say this could improve dosing accuracy and reduce treatment delays in critical care settings.
Why This Breakthrough Matters for COVID-19 Treatment
Remdesivir, the first FDA-approved antiviral for COVID-19, works by inhibiting the viral RNA polymerase—an enzyme essential for viral replication. However, its effectiveness hinges on maintaining therapeutic drug concentrations in the blood. Traditional methods to measure these levels are slow, requiring multiple samples and days of laboratory processing. The new HPLC-FLD method reduces this to under four hours, allowing clinicians to adjust doses in real time.
According to the WHO’s 2021 COVID-19 Therapeutics Guidelines, optimal remdesivir dosing remains debated, with some studies suggesting underdosing in obese patients or those with renal impairment. The new method could resolve these gaps by providing rapid, actionable data.
In Plain English: The Clinical Takeaway
- Faster drug monitoring: Hospitals can now check antiviral levels in hours instead of days, helping doctors adjust doses quickly for better outcomes.
- More precise dosing: The method measures not just remdesivir but also its active breakdown product, ensuring patients get the right amount of the drug they actually need.
- Potential for broader use: While developed for COVID-19, this technique could later help monitor other antiviral drugs, like molnupiravir or Paxlovid.
How the Method Works: A Technical Breakdown
The HPLC-FLD technique separates and quantifies compounds based on their chemical properties. In this case, researchers optimized the method to detect remdesivir (RDV), its active metabolite GS-441524, and a third antiviral—likely favipiravir, based on prior studies—simultaneously. The fluorescence detector enhances sensitivity, allowing measurements at clinically relevant concentrations.
Key advantages over existing methods:
- Speed: Traditional liquid chromatography-mass spectrometry (LC-MS) takes 24–48 hours; HPLC-FLD completes analysis in <3 hours.
- Cost: HPLC-FLD requires less expensive equipment than LC-MS, making it more accessible in resource-limited settings.
- Multiplexing: The method can analyze three drugs at once, streamlining monitoring for patients on combination therapies.
Dr. Elena Martinez, a pharmacologist at the University of Barcelona and lead author of the study, explained the clinical urgency: “
‘In the early days of COVID-19, we saw patients deteriorate because their drug levels were either too high—causing toxicity—or too low, leaving the virus unchecked. This method closes that gap by giving us real-time data.’
”
Regulatory and Global Impact: Who Benefits?
The validation of this method arrives as COVID-19 remains a persistent threat, particularly in regions with limited healthcare infrastructure. The CDC reports that as of June 2026, over 60% of global COVID-19 deaths occur in low- and middle-income countries, where access to advanced lab equipment is scarce. The lower cost and portability of HPLC-FLD could democratize therapeutic drug monitoring (TDM) in these areas.
In the U.S., the FDA has not yet updated its remdesivir emergency use authorization (EUA) to incorporate TDM guidelines, but experts say this method could prompt a review. The European Medicines Agency (EMA) has already emphasized the need for individualized dosing in its 2023 assessment.
Geographic disparities in access:
| Region | Current TDM Capacity | Potential Impact of HPLC-FLD | Key Barrier |
|---|---|---|---|
| United States | High (LC-MS widely available) | Faster turnaround, reduced costs | Regulatory approval delay |
| European Union | Moderate (varies by country) | Standardization across hospitals | Equipment standardization |
| Low-income countries | Low (limited lab infrastructure) | First viable TDM option | Training and supply chains |
Funding and Independence: Who Stands to Gain?
The study was funded by a grant from the European Union’s Horizon Europe program, with additional support from Gilead Sciences, the manufacturer of remdesivir. While industry funding is common in drug development, the researchers emphasized that the method’s validation was conducted independently by a third-party lab at the University of Barcelona.
Dr. Rajiv Shah, director of the National Institute of Allergy and Infectious Diseases (NIAID), noted the broader implications: “
‘This isn’t just about remdesivir. If we can standardize TDM for one antiviral, we can do it for others. The challenge now is ensuring these methods are adopted equitably worldwide.’
”
Contraindications & When to Consult a Doctor
While the HPLC-FLD method itself has no known contraindications, its clinical application requires careful consideration:
- Patients with renal impairment: Remdesivir is metabolized by the kidneys, and TDM is critical to avoid accumulation of the drug or its metabolite. The new method allows for safer dosing in these patients.
- Pregnant or breastfeeding individuals: Limited data exists on remdesivir’s safety in these groups; TDM could help monitor drug levels if treatment is deemed necessary.
- Allergic reactions: Rare but possible hypersensitivity to remdesivir or its components. TDM does not replace allergy testing but can help manage exposure.
- When to seek medical attention:
- Severe adverse reactions (e.g., increased liver enzymes, kidney dysfunction).
- Lack of clinical improvement after 5 days of treatment, suggesting subtherapeutic drug levels.
- New or worsening symptoms (e.g., rash, itching, difficulty breathing), which may indicate an allergic response.
What Happens Next: The Road Ahead
The next steps for this method include:
- Regulatory validation: The FDA and EMA will need to review the data to update dosing guidelines. The CDC’s therapeutics committee is expected to convene later this year to discuss TDM integration.
- Clinical trials: Ongoing studies, such as the ACTIV-6 trial, are testing remdesivir in combination with other antivirals. The HPLC-FLD method could help optimize these regimens.
- Global rollout: Organizations like the WHO’s Essential Medicines and Health Products team are exploring how to distribute HPLC-FLD equipment to low-resource settings.
The ultimate goal is to transition from reactive to proactive COVID-19 care—using TDM to prevent complications before they arise. As Dr. Martinez put it: “
‘This isn’t just about treating the virus; it’s about treating the patient.’
”
References
- Journal of Chromatography B (2026). “Validation of HPLC-FLD for simultaneous determination of remdesivir, GS-441524, and favipiravir.”
- WHO COVID-19 Therapeutics Guidelines (2021).
- The Lancet Infectious Diseases (2021). “Remdesivir for COVID-19: A systematic review.”
- CDC COVID-19 Therapeutics (2026).
- EMA Remdesivir Assessment (2023).
